Next Article in Journal
Quality by Design-Based Development of Solid Self-Emulsifying Drug Delivery System (SEDDS) as a Potential Carrier for Oral Delivery of Lysozyme
Previous Article in Journal
Does Green Exfoliation of Graphene Produce More Biocompatible Structures?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 3
10.3390/pharmaceutics15030994
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Pharmaceutics 2022, 14(12), 2668.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. Pharmaceutics 2022, 14, 2668

by
Amira Mansour
1,
Mohamed Y. Mahmoud
2,
Alaa F. Bakr
3,
Monira G. Ghoniem
4,
Fatima A. Adam
4 and
Ibrahim M. El-Sherbiny
1,*
1
Nanomedicine Research Labs, Center for Materials Science, Zewail City of Science & Technology, Giza 12578, Egypt
2
Department of Toxicology and Forensic Medicine, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt
3
Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt
4
Department of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia
*
Author to whom correspondence should be addressed.
Pharmaceutics 2023, 15(3), 994; https://doi.org/10.3390/pharmaceutics15030994
Submission received: 8 March 2023 / Accepted: 13 March 2023 / Published: 20 March 2023
Versions Notes
In the original publication [1], specifically in Section 2.9. In Vivo Assessment, paragraph 1, lines 2–4, there is a need to correct some details in the ethical approval of the in vivo study.
We also highlighted the changes in Section 2.9. In Vivo Assessment, paragraph 1, lines 2–4, as well as in the Institutional Review Board Statement, with the following text.
“The in vivo experiment was performed after receiving the approval from the Institutional Animal Care and Use Committee (ARC-IACUC), Cairo, Egypt (protocol number: ARC-AH-22-29)”
“Institutional Review Board Statement: The in vivo experiment was performed after receiving the approval from the Institutional Animal Care and Use committee (ARC-IACUC), Cairo, Egypt (Protocol number: ARC-AH-22-29) that complies with the United Kingdom Animals Scientific Procedures Act, 1986, and the European Union directive 2010/63/EU for animal experiments, as well as the ARRIVE guidelines.”
The authors apologize for any inconvenience caused and the state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Mansour, A.; Mahmoud, M.Y.; Bakr, A.F.; Ghoniem, M.G.; Adam, F.A.; El-Sherbiny, I.M. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. Pharmaceutics 2022, 14, 2668. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mansour, A.; Mahmoud, M.Y.; Bakr, A.F.; Ghoniem, M.G.; Adam, F.A.; El-Sherbiny, I.M. Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. Pharmaceutics 2022, 14, 2668. Pharmaceutics 2023, 15, 994. https://doi.org/10.3390/pharmaceutics15030994

AMA Style

Mansour A, Mahmoud MY, Bakr AF, Ghoniem MG, Adam FA, El-Sherbiny IM. Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. Pharmaceutics 2022, 14, 2668. Pharmaceutics. 2023; 15(3):994. https://doi.org/10.3390/pharmaceutics15030994

Chicago/Turabian Style

Mansour, Amira, Mohamed Y. Mahmoud, Alaa F. Bakr, Monira G. Ghoniem, Fatima A. Adam, and Ibrahim M. El-Sherbiny. 2023. "Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. Pharmaceutics 2022, 14, 2668" Pharmaceutics 15, no. 3: 994. https://doi.org/10.3390/pharmaceutics15030994

APA Style

Mansour, A., Mahmoud, M. Y., Bakr, A. F., Ghoniem, M. G., Adam, F. A., & El-Sherbiny, I. M. (2023). Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. Pharmaceutics 2022, 14, 2668. Pharmaceutics, 15(3), 994. https://doi.org/10.3390/pharmaceutics15030994

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop